News & Events

November 04, 2018

VIDAC PHARMA TO PRESENT A POSTER AT THE SITC 2018 MEETING

Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster…
July 10, 2018

VIDAC PHARMA ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early…
June 20, 2018

VIDAC PHARMA TO PRESENT A POSTER AT THE EACR25 2018 MEETING

Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the…
April 04, 2018

VIDAC PHARMA TO PRESENT AN IMMUNO-METABOLISM POSTER AT THE 2018 AACR ANNUAL MEETING 2018

Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present an immono-metabolism poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The poster…
Jan 23, 2018

VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE

Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and…
Dec 06, 2017

VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM

Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and…
Oct 12, 2017

VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS

Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102…
Jan 01, 2017

VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS

Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused…
Dec 12, 2016

VIDAC PHARMA PHASE 2A STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION

Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused…
Jul 29, 2016

VIDAC PHARMA ANNOUNCES THE INNITIATION OF A PHASE 2A STUDY OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 30, 2016

VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT

Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 29, 2016

Vidac Pharma Completes $9 Million Series A Financing I Advances Phase 2 Studies with VDA-1102 In Actinic Keratosis

Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage…
Feb 25, 2016

Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development…
Dec 30, 2015

Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis

Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development…
Oct 15, 2014

Vidac Pharma Appoints Dr. Chaim Brickman as Vice President of Clinical Affairs

Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development…
Aug 19, 2014

Vidac Pharma Appoints Dr. Paul Salama as Vice President of Chemistry, Manufacturing, and Control

Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development…

 

back Factsheet